natgillin/translations-raw huggingface dataset:
Reconcile tablets are used as an aid in the treatment of separation-related disorders in dogs, such as destruction and vocalisation and inappropriate defaecation and/ or urination.
Tablete Reconcile se uporabljajo kot pripomoček pri zdravljenju motenj, povezanih z ločitvijo, ki se pri psih kaže v uničevanju in nesprejemljivem obnašanju ter lajanju in neustrezni defekaciji oziroma uriniranju.
Do not use Reconcile in dogs with epilepsy or a history of seizures.
Zdravila Reconcile ni možno uporabljati pri psih z epilepsijo ali psih z anamnezo napadi krčev.
28/ 33 This product should not be used in case of hypersensitivity to fluoxetine or other Selective Serotonin Re-uptake Inhibitors (SSRIs).
Izdelka ne smete uporabljati v primeru pretirane občutljivosti na fluoksetin ali drugih selektivnih inhibitorjev prisvajanja serotonina (SSRI).
- Very common adverse events: decreased appetite (including anorexia); lethargy (including calmness
- Zelo pogosti neželeni učinki: zmanjšan tek (vključno z anoreksijo); letargija (vključno z mirnostjo in
and increased sleeping)
povečano zaspanostjo)
- Common adverse events: urinary tract disorders (such as bladder infections, irregular urination,
- Pogosti neželeni učinki: motnje urinarnega trakta (infekcije mehurja, neredno uriniranje, boleče
discomfort in passing urine); central nervous system signs (incoordination, disorientation)
uriniranje); motnje centralnega živčnega sistema (nekoordiniranost gibov, izguba orientacije)
- Uncommon adverse events: weight loss/ loss of condition; dilation of the pupils of the eye
- Manj pogosti neželeni učinki: hujšanje oziroma izguba kondicije; dilatacija zenic v očesu
- Rare adverse events: seizures
- Redki neželeni učinki: napadi krčev
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
ODMERKI O POSAMEZNE ŽIVALSKE VRSTE TER POTI IN NAČIN UPORABE ZDRAVILA
Body
Telesna
Number of tablets
Število tablet na dan
The dog’ s response to therapy should be evaluated by the veterinary surgeon.
Odziv psa na terapijo mora oceniti veterinar.
Clinical improvement is expected within 1 or 2 weeks.
Klinično izboljšanje se lahko pričakuje v 1 do 2 tednih.
If no improvement is noted within 4 weeks, consult your veterinary surgeon who will need to re-evaluate the dog’ s treatment.
Če po 4 tednih ne opazite izboljšanja, se obrnite na vašega veterinarja, ki bo na novo premislil o načinu zdravljenja psa.
Professional judgement should be used in monitoring the patient’ s response to therapy to determine the need for continued treatment beyond 8 weeks or discontinuation of treatment should adverse events warrant.
Pri opazovanju reakcij pacienta na terapijo mora strokovnjak oceniti, če je zdravljenje treba nadaljevati tudi po 8 tednih ali ga prekiniti, ker na to kažejo neželeni učinki.
Reconcile tablets may be given with or without food and are flavoured so that most dogs will consume the tablet when offered by the owner.
Tablete Reconcile se lahko dajejo s hrano ali brez nje ter so prijetnega okusa in bo večina psov z veseljem pojedla tableto, ki mu jo da lastnik.
ADVICE ON CORRECT ADMINISTRATION
NASVET ZA PRAVILNO UPORABO ZDRAVILA
Shelf-life after first opening the container:
Rok uporabnosti po prvem odpiranju posode:
Do not use after the expiry date which is stated on the bottle.
Ne uporabljajte po datumu izteka roka uporabnosti, navedenega na posodi.
The safety of Reconcile has not been established in dogs weighing less than 4 kg, or under 6 months of age.
Varnost zdravila Reconcile se ni preverila pri psih z manj kot 4 kg telesne teže ali pod starostjo 6 mesecev.
Studies to determine the effects of Reconcile tablets on breeding, pregnant or lactating dogs have not been conducted and thus the use in pregnant and lactating dogs is not recommended.
Študij o učinkih tablet Reconcile na breje ali doječe psice ni in se zato ne priporoča uporaba pri brejih ali doječih psicah.
Reconcile tablets should not be used in dogs with epilepsy or a history of seizures.
Tablet Reconcile ni možno uporabljati pri psih z epilepsijo ali psih z anamnezo napadi krčev.
Please inform your veterinary surgeon if your dog is receiving, or has had, any other medicines, even those not prescribed, as Reconcile tablets should not be given at the same time as many other medicines.
Če svojemu psu ste dajali ali dajete druga zdravila, tudi brez recepta, o tem obvestite svojega veterinarja, saj se tablete Reconcile ne smejo dajati sočasno z večino drugih zdravil.
Further advice for the veterinary surgeon - see section 4.8 of the Summary of Product Characteristics for further information on interactions with other medicinal products.
Dodatna navodila za veterinarje - Gl. točko 4. 8 Povzetka glavnih značilnosti zdravila za dodatne informacije o medsebojnem učinku z drugimi zdravili.
(For further information see section 4.10 of the Summary of Product Characteristics).
(Za dodatne informacije gl. točko 4. 10 Povzetka glavnih značilnosti izdelka).
Any unused product or waste material should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadne snovi odvrzite v skladu z ustrezno zakonodajo v vaši državi.
Medicines should not be disposed of via wastewater or household waste.
Zdravila se ne smejo metati v vodo ali gospodinjske odpadke.
Ask your veterinary surgeon how to dispose of medicines no longer required.
Posvetujte se s svojim veterinarjem, kako odvreči zdravila, ki jih ne potrebujete več.
These measures should help to protect the environment.
Na ta način lahko prispevate k varovanju okolja.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu /
The tablets are packaged in HDPE bottles, each bottle containing 30 tablets with a cotton coiler and desiccant canister.
Tablete so pakirane v plastenke iz HDPE; vsaka plastenka vsebuje po 30 tablet, kosmič vate in kanister s sušilnim sredstvom.
For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
Za vse dodatne informacije o tem zdravilu se obrnite na krajevno predstavništvo imetnika dovoljenja za promet z zdravilom.
Rheumocam is a yellowish opaque oral suspension which is to be given mixed with food.
Zdravilo Rheumocam je rumenkasta motna peroralna suspenzija, ki se jo daje pomešano med hrano.
Rheumocam contains the active substance meloxicam in a strength of 1.5 mg/ ml.
Zdravilo Rheumocam vsebuje zdravilno učinkovino meloksikam v jakosti 1, 5 mg/ ml.
Rheumocam is a ‘ generic ’ which means that Rheumocam is similar to a ‘ reference veterinary medicine ’ already authorised in the EU (Metacam 1.5 mg/ ml oral suspension).
Rheumocam je generično zdravilo, kar pomeni, da je podobno „ referenčnemu veterinarskemu zdravilu “, ki je bilo v EU že odobreno (Metacam 1, 5 mg/ ml peroralna suspenzija).
Studies have been carried out to prove that Rheumocam is ‘ bioequivalent ’ to the reference veterinary medicine which means that Rheumocam is equivalent to Metacam 1.5 mg/ ml suspension in the way it is absorbed and used by the body.
Za dokazovanje biološke enakovrednosti zdravila Rheumocam z referenčnim veterinarskim zdravilom so bile izvedene študije, kar pomeni, da je zdravilo Rheumocam enakovredno zdravilu Metacam 1, 5 mg/ ml suspenzija, in sicer po načinu, na katerega ga telo absorbira in uporablja.
Rheumocam is used in dogs to relieve inflammation and pain in musculo-skeletal disorders.
Zdravilo Rheumocam se uporablja pri psih za lajšanje vnetja in bolečin pri kostno- mišičnih obolenjih.
Rheumocam is given to the dog once a day, with food, at the dose of 0.2 mg meloxicam/ kg body weight on the first day, then at 0.1 mg/ kg afterwards.
Zdravilo Rheumocam se psu daje enkrat dnevno s hrano v odmerku 0, 2 mg meloksikama na kg telesne mase prvi dan, zatem pa v odmerku 0, 1 mg/ kg.
The amount of suspension to be used is measured using a special dosing syringe (provided in the product package) and poured on the food.
Količino suspenzije, ki jo želimo uporabiti, odmerimo s posebno merilno brizgo (priloženo zdravilu) in jo izbrizgamo v hrano.
Rheumocam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo Rheumocam vsebuje meloksikam, ki spada v skupino zdravil, ki jim pravimo nesteroidna protivnetna zdravila (NSPVZ).
How has the effectiveness of Rheumocam been studied?
Kako je bila raziskana učinkovitost zdravila Rheumocam?
A study looked at how Rheumocam was absorbed and its effects in the body, in comparison with Metacam 1.5 mg/ ml oral suspension.
V študiji so preučevali absorbiranje zdravila Rheumocam ter njegove učinke na telo v primerjavi z zdravilom Metacam 1, 5 mg/ ml peroralna suspenzija.
Reproduction is authorised provided the source is acknowledged What are the side-effects of Rheumocam?
Reproduction is authorised provided the source is acknowledged Kakšni so neželeni učinki zdravila Rheumocam?
Occasional side effects of Rheumocam are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools and apathy (lack of vitality).
Občasni neželeni učinki zdravila Rheumocam so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in obsegajo izgubo apetita, bruhanje, drisko, kri v blatu in apatijo (pomanjkanje vitalnosti).
These side effects occur generally within the first week of treatment and are usually temporary and disappear once treatment has stopped.
Ti neželeni učinki se običajno pojavijo v prvem tednu zdravljenja in so navadno začasni ter izginejo ob prenehanju zdravljenja.
People who are hypersensitive (allergic) to NSAIDs should avoid contact with Rheumocam.
Osebe, ki so preobčutljive za (alergične na) nesteroidna protivnetna zdravila, naj se izogibajo stiku z zdravilom Rheumocam.
If the product is swallowed by a person, the advice of a doctor should be sought immediately.
V primeru, da zdravilo zaužije človek, se je treba nemudoma posvetovati z zdravnikom.
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Rheumocam has been shown to be bioequivalent to Metacam 1.5 mg/ ml oral suspension.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da se je zdravilo Rheumocam v skladu z zahtevami Evropske unije izkazalo kot biološko enakovredno zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija.
Therefore the CVMP’ s view was that, as for Metacam 1.5 mg/ ml oral suspension, Rheumocam’ s benefits are greater than its risks when treating inflammation or pain in muscles or joints in dogs and they recommended that Rheumocam should be given a marketing authorisation.
CVMP je zato menil, da so koristi zdravila Rheumocam, tako kot zdravila Metacam 1, 5 mg/ ml peroralna suspenzija, večje od z njim povezanih tveganj pri zdravljenju vnetij ali bolečin v mišicah ali sklepih pri psih, ter je priporočil odobritev dovoljenja za promet z zdravilom Rheumocam.
The European Commission granted a marketing authorisation valid throughout the European Union, for Rheumocam to Chanelle Pharmaceuticals Manufacturing Ltd. on 10.01.2008.
Evropska komisija je dovoljenje za promet z zdravilom Rheumocam, veljavno po vsej Evropski uniji, odobrila družbi Chanelle Pharmaceutical Manufacturing Ltd.
This summary was last updated:
Povzetek je bil nazadnje posodobljen:
Invented Name
Lastniško ime
1.5 mg/ ml Oral suspension Dogs
Peroralna suspenzija
PET bottle polypropylene measuring syringe
PET plastenka, polipropilensko odmerno brizgalko
1 bottle with N/ A dosing syringe
1 plastenka z odmerno brizgalko
Oral use
Psi
HDPE bottle polypropylene measuring syringe
Peroralna uporaba
15 ml
Steklenička iz polietilena 15 ml visoke, polipropilensko odmerno brizgalko
Rheumocam 1.5 mg/ ml oral suspension for dogs
Rheumocam 1, 5 mg/ ml, peroralna suspenzija za pse
Each ml of Rheumocam 1.5 mg/ ml oral suspension contains:
1 ml peroralne suspenzije Rheumocam 1, 5 mg/ ml vsebuje:
Meloxicam 1.5 mg
Meloksikam 1, 5 mg
Excipient:
Pomožna( e) snov( i):
Sodium benzoate 5 mg
Natrijev benzoat 5 mg
4.7 Use during pregnancy, lactation or lay
4. 7 Uporaba v obdobju brejosti, laktacije ali valjenja
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3).
Varnost veterinarskega zdravila med brejostjo in laktacijo ni raziskana (glejte poglavje 4. 3).
The suspension can be given using the Rheumocam measuring syringe provided in the package.
Suspenzijo lahko dajemo s priloženo merilno brizgo za Rheumocam.
0.1 mg meloxicam/ kg body weight).
Brizga je oblikovana tako, da se prilega plastenki in ima merilno skalo z oznakami telesne mase v kilogramih, ki ustrezajo vzdrževalnemu odmerku (0, 1 mg meloksikama na kilogram telesne mase).
Anti-inflammatory and Anti-rheumatic products, Non-steroids ATC vet code:
Farmakoterapevtska skupina: protivnetna in protirevmatična zdravila, nesteroidna Oznaka ATCvet:
Saccharin Sodium Sodium Carboxyl Methyl Cellulose Colloidal Silicon Dioxide Citric Acid Monohydrate Sorbitol Solution Disodium Hydrogen-Phosphate Dodecahydrate Sodium Benzoate Honey Flavour.
natrijev saharinat natrijeva karboksimetilceluloza silicijev dioksid,, koloidni, brezvodni citronska kislina monohidrat raztopina sorbitola natrijev hidrogenfosfat dodekahidrat natrijev benzoat aroma medu.
4 Shelf life of the veterinary medicinal product as packaged for sale:
Rok uporabnosti zdravila v pakiranju za prodajo:
2 years Shelf life after first opening the immediate packaging:
2 leti Rok uporabnosti po prvem odpiranju stične ovojnine:
42, 100 or 200 ml polyethylene terephthalate (PET) bottle with a tamper resistant child proof closure, and a 15 ml HDPE bottle with a tamper resistant child proof closure, and a polypropylene measuring syringe.
Polietilen tereftalata (PET) plastenka po 42, 100 ali 200 ml z varnostnim, za otroke varnim zapiralom, in steklenička iz polietilena visoke gostote 15 ml z varnostnim, za otroke varnim zapiralom, ter polipropilenska merilna brizga.
Galway, Ireland.
Galway, Irska.
Tel: + 353 91 841788 Fax: + 353 91 842937 e-mail: sales@chanellegroup. ie
Tel: + 353 91 841788 Faks: + 353 91 842937 e- pošta: sales@ chanellegroup. ie
5 Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
5 Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu.
Galway, IRELAND.
Galway, IRSKA.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE ALI UPORABE
Each ml contains:
1 ml vsebuje:
1.5 mg of meloxicam 5 mg of sodium benzoate
1, 5 mg meloksikama 5 mg natrijevega benzoata
EXP {month/ year} Once opened use within 6 months.
EXP {mesec/ leto} Odprto zdravilo uporabite v 6 mesecih.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
BESEDILO “ SAMO ZA ŽIVALI ” TER POGOJI IN OMEJITVE GLEDE OSKRBE IN UPORABE, če je navedba smiselna
12 BN{number}
Številka serije {številka}
13 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
PRIMARNI OVOJNINI
{Label for 100ml and 200ml bottles}
{Nalepka za 100 ml in 200 ml plastenke}
BN{number}
Številka serije {številka}
{Label for 15ml and 42 ml bottle}
{Nalepka za 15 ml ali 42 ml plastenko}
Meloxicam 1.5 mg/ ml
Meloksikam 1, 5 mg/ ml
Dogs.
18 Psi.
The following dosing table indicates what volume to administer depending on the weight of the dog:
Naslednja tabela za odmerjanje prikazuje, kakšen volumen je treba dati v odvisnosti od mase psa:
Bodyweight (kg) 7.5 15 22.5 30 37.5 45 52.5 60
Telesna masa (kg) 7. 5 15 22. 5 30 37. 5 45 52. 5 60
Maintenance Dosage (ml) 0.5 1 1.5 2 2.5 3 3.5 4
Vzdrževalni odmerek (ml) 0. 5 1 1. 5 2 2. 5 3 3. 5 4
19 If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
19 Če se pojavijo neželeni učinki, je treba zdravljenje prekiniti in se posvetovati z veterinarjem.
15, 42, 100 or 200 ml bottle with a measuring syringe.
Plastenke po 15, 42, 100 ali 200 ml z merilno brizgo.
What is SevoFlo?
Kaj je zdravilo SevoFlo?
SevoFlo is 100% sevoflurane, a chemical which is a liquid at room temperature, but, when heated, becomes a gas (vaporises).
Zdravilo SevoFlo je 100% sevofluran, t. j. kemična snov, ki je pri sobni temperaturi tekoča, pri segrevanju pa se uplini (upari).
This gas is used as a general anaesthetic for dogs.
Ta plin se uporablja kot splošni anestetik za pse.
What is SevoFlo used for?
Za kaj se zdravilo SevoFlo uporablja?
SevoFlo is used both to induce and maintain anaesthesia in dogs.
Zdravilo SevoFlo se uporablja za uvod v anestezijo in njeno vzdrževanje pri psih.
SevoFlo is administered using specialised anaesthetic equipment, usually in a carefully controlled gas mixture including oxygen.
Zdravilo SevoFlo se daje s pomočjo specializirane opreme za anestezijo, običajno v obliki natančno regulirane plinske mešanice, v kateri je tudi kisik.
When a dog is given a mixture of oxygen and sevoflurane to breathe, the sevoflurane is inhaled into its lungs, from where it goes into the blood stream, crosses into the brain and induces an unconscious state.
Ko pes dobi mešanico kisika in sevoflurana za vdihavanje, inhalira sevofluran v pljuča, kjer le- ta preide v krvni obtok, potuje v možgane in izzove stanje nezavesti.
At the end of surgery, the anaesthetic is discontinued.
Po koncu operacije se dajanje anestetika prekine.
When the concentration of anaesthetic in the brain drops below a certain level the dog wakes up.
Ko se koncentracija anestetika v možganih spusti pod določeno raven, se pes prebudi.
How has SevoFlo been studied?
Kako je bilo zdravilo SevoFlo raziskano?
Data were provided on the pharmaceutical quality, the tolerance of the product in dogs, and its safety in humans (people in contact with the product) and the environment.
Predloženi so bili podatki o farmacevtski kakovosti, kako psi prenašajo zdravilo ter o varnosti za ljudi (ljudi, ki so v stiku z zdravilom) in okolje.
Studies were carried out in dogs, comparing the effectiveness of SevoFlo to that of other anaesthetic agents, such as isoflurane (another anaesthetic gas), thiopental, propofol, and ketamine plus diazepam, and SevoFlo’ s effectiveness at both inducing and maintaining anaesthesia was investigated.
Izvedene so bile raziskave pri psih, v katerih so primerjali učinkovitost zdravila SevoFlo z učinkovitostjo drugih anestetikov, kot so na primer izofluran (drug anestezijski plin), tiopental, propofol in ketamin z diazepamom, ter učinkovitost zdravila SevoFlo pri uvodu v anestezijo in njenem vzdrževanju.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has SevoFlo shown during the studies?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 47 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo SevoFlo izkazalo med raziskavami?
In the studies, SevoFlo was equally efficacious when compared to other anaesthetic agents.
V raziskavah je bilo zdravilo SevoFlo enako učinkovito kot drugi anestetiki.
Studies showed that sevoflurane could safely be used with several other medicines commonly used in dogs before or during operations.
Raziskave so pokazale, da je sevofluran mogoče varno uporabljati z več drugimi zdravili, ki se pogosto uporabljajo pri psih pred ali med operacijami.
What is the risk associated with SevoFlo?
Kakšna tveganja so povezana z zdravilom SevoFlo?
The most frequently reported side effects associated with SevoFlo administration in dogs are low blood pressure, abnormally rapid breathing, muscle tenseness, excitation, a temporary inability to breathe, small muscle twitches, and vomiting.
Najpogostejši neželeni učinki, o katerih so poročali v povezavi z uporabo zdravila SevoFlo pri psih, so nizek krvni tlak, nenormalno hitro dihanje, napetost v mišicah, razdraženost, začasna nezmožnost dihanja, majhne kontrakcije mišic in bruhanje.
The dose used for very old or very sick dogs may need to be adjusted.
Pri zelo starih ali zelo bolnih psih je uporabljeni odmerek morda treba prilagoditi.
SevoFlo should not be used in pregnant or lactating bitches or in dogs less than 12 weeks of age as there is limited clinical experience.
Zdravilo SevoFlo se naj ne uporablja pri brejih ali doječih psicah ali pri psih, mlajših od 12 tednov, saj so pri njih klinične izkušnje omejene.
SevoFlo should not be used in dogs with a known or suspected sensitivity to such anaesthetics.
Zdravilo SevoFlo se ne sme uporabljati pri psih z znano preobčutljivostjo za anestetike ali s sumom nanjo.
For a full list of all side-effects reported with SevoFlo, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila SevoFlo, glejte Navodilo za uporabo.
This veterinary medicine has been developed especially for dogs and is not intended for use in humans.
To veterinarsko zdravilo je bilo razvito posebej za pse in ni namenjeno za uporabo pri ljudeh.
As sevoflurane is a general anaesthetic, human exposure to sevoflurane vapour may cause symptoms such as shivering, nausea, headaches, low blood pressure, decreased heart rate and even reduced breathing.
Človeška izpostavljenost hlapom sevoflurana lahko povzroči simptome, kot so tresavica, slabost, glavobol, nizek krvni tlak, zmanjšan srčni utrip in celo zmanjšano dihanje.
Care must therefore be taken to remove any spillage immediately, the vapour should not be inhaled, and all contact with the product by mouth must be avoided.
Morebitno razlito zdravilo je zato treba odstraniti takoj, hlapov ne vdihavajte, prav tako se izogibajte vsakršnemu stiku z zdravilom prek ust.
Pregnant and breast-feeding women should not have any contact with the product and should also avoid operating rooms and animal recovery areas where the product is being, or has recently been, used.
Nosečnice in doječe matere ne smejo priti v stik z zdravilom, zato se morajo izogibati operacijskim sobam in prostorom za prebujanje živali, v katerih se zdravilo uporablja oziroma se je nedavno uporabljalo.
In case of accidental contact with the skin or eyes, or for more information, the Package Leaflet should be consulted.
Če pride do nenamernega stika s kožo ali očmi ali če želite več informacij, si preberite Navodilo za uporabo.
Why has SevoFlo been approved?
Zakaj je bilo zdravilo SevoFlo odobreno?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of SevoFlo exceed the risks in relation to its use for the induction and maintenance of anaesthesia in dogs and recommended that SevoFlo be given a marketing authorisation.
Zato je priporočil, da se za zdravilo SevoFlo odobri dovoljenje za promet.
Other information about SevoFlo:
Druge informacije o zdravilu SevoFlo:
The European Commission granted a marketing authorisation valid throughout the European Union, for SevoFlo to Abbott Laboratories Ltd on 11 December 2002.
Evropska komisija je dovoljenje za promet z zdravilom SevoFlo, veljavno po vsej Evropski uniji, odobrila družbi Abbott Laboratories Ltd dne 11. decembra 2002.
Information on the prescription status of this product may be found on the outer package.
Informacije o predpisovanju tega izdelka najdete na ovojnini.
This summary was last updated in March 2007.
Ta povzetek je bil nazadnje posodobljen 03- 2007.
EU Number
Številka dovoljenja za promet
Bottle (polyethylene naphthalate) with Quik-Fil (II) closure
Plastenka iz polietilennaftalata (PEN) z zaporko Quik- Fil (II)
SevoFlo 100% Inhalation vapour, liquid for dogs.
SevoFlo, 100% para za inhaliranje, tekočina za pse.
Each bottle contains 250 ml sevoflurane (100%).
Vsaka steklenica vsebuje 250 ml sevoflurana (100%).